Tempus AI stock rises 3.5% after unveiling HRD-RNA algorithm for cancer detection

Tempus AI Unveils Advanced Cancer Detection Tool

Tempus AI stock performance improved Wednesday, rising 3.5% after the precision medicine company announced the launch of its HRD-RNA algorithm, a next-generation AI algorithm designed to detect homologous recombination deficiency (HRD) in tumors1

1

2

2

. The innovative tool marks a significant advancement in cancer detection, offering physicians a more functional view of tumor biology through gene expression analysis rather than relying solely on traditional DNA-based genomic testing methods.

How the HRD-RNA Algorithm Transforms Tumor Biology Assessment

The 1,660-gene logistic regression model represents a departure from conventional approaches to identifying patients who may benefit from platinum-based chemotherapy or PARP inhibitors2

2

. Unlike traditional DNA tests that analyze static "genomic scars," Tempus AI's RNA-based approach provides real-time assessment of a tumor's functional status by examining the transcriptome. This methodology enables the detection of HRD in patients and cancer types where genomic scarring proves difficult to identify through standard methods. Chief Development Officer Halla Nimeiri emphasized that by examining the transcriptome, physicians gain access to a functional HRD status that is more dynamic than what the genome alone can reveal1

1

.

Validation Study Shows Promise for Metastatic Pancreatic Cancer Treatment Options

A real-world validation study demonstrated compelling results for the HRD-RNA algorithm's clinical utility. HRD-RNA-positive metastatic pancreatic cancer patients who received first-line platinum-based regimens experienced a significant mortality risk reduction compared with those receiving non-platinum therapies1

1

2

2

. The complete supporting data from this validation study will be published later this year, providing the medical community with detailed insights into the algorithm's effectiveness across different patient populations.

Precision Medicine Advancement and Market Implications

Tempus AI plans to make the test clinically available later this year, though it currently remains available for research use only2

2

. This launch positions Tempus AI as a leader in precision medicine, potentially expanding its market reach and improving patient outcomes through more targeted treatment selection. The company is set to report earnings on February 24, 2026, with revenue estimates reaching $364.25 million, up from $200.68 million year-over-year1

1

. Analysts maintain a Buy Rating with an average price target of $76.60, suggesting confidence in the company's trajectory despite current stock performance challenges. The stock trades 8.3% below its 20-day simple moving average and 25.8% below its 100-day SMA, indicating near-term pressure1

1

. However, the algorithm's potential to identify previously undetectable HRD cases could catalyze growth as adoption increases across oncology practices seeking better tools for treatment decision-making.